PYXS

Pyxis Oncology Inc
1.60
-0.01 (-0.62%)
Upgrade to Real-Time
Afterhours (Closed)
1.60
Volume 17,941
Bid Price 1.59
Ask Price 1.67
News -
Day High 1.665

Low
1.10

52 Week Range

High
9.57

Day Low 1.5901
Company Name Stock Ticker Symbol Market Type
Pyxis Oncology Inc PYXS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.62% 1.60 16:02:28
Open Price Low Price High Price Close Price Prev Close
1.64 1.5901 1.665 1.60 1.61
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
175 17,941 $ 1.64 $ 29,347 - 1.10 - 9.57
Last Trade Time Type Quantity Stock Price Currency
16:00:00 70 $ 1.61 USD

Period:

Draw Mode:

Pyxis Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 56.16M 35.10M 34.74M $ - $ - -9.45 -0.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 193.11k 8.60%

more financials information »

Pyxis Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PYXS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.611.69011.531.63325,414-0.01-0.62%
1 Month1.451.69011.381.60108,8880.1510.34%
3 Months1.481.69011.101.40180,6750.128.11%
6 Months2.813.11481.101.54117,077-1.21-43.06%
1 Year8.519.571.102.32141,477-6.91-81.2%
3 Years19.0019.001.105.29160,164-17.40-91.58%
5 Years19.0019.001.105.29160,164-17.40-91.58%

Pyxis Oncology Description

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.